VVOS Vivos Therapeutics, Inc.
Data as of close
Healthcare · Surgical & Medical Instruments & Apparatus
Vivos Therapeutics, Inc. (VVOS) is a healthcare company in the Surgical & Medical Instruments & Apparatus industry, with a market capitalization of $2 million. Shares last traded at $0.11, 95.8% below their 52-week high. Over the past year the stock is down 95.6%. Net profit margin is -121.8%, below the peer median of -6.3%. Revenue grew 16.0% year over year.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · split-adjusted · Databento EQUS.MINI. VVOS split history →
Technicals
Financials
Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | -$0.31 | 2026-08-14 |
| Q1 2026 | -$0.52 | 2026-05-20 |
| Q4 2025 (derived) | -$0.58 | 2026-04-15 |
| FY 2025 | -$2.07 | 2026-04-15 |
| Q3 2025 | -$0.49 | 2025-11-19 |
| Q2 2025 | -$0.55 | 2025-08-19 |
Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.
Surgical & Medical Instruments & Apparatus peers
VVOS vs 14 industry peers (Surgical & Medical Instruments & Apparatus), by market cap. Data as of close
| SYK | Stryker Corporation | $118.2B | 32.63 | 4.50 | 13.8% | +1.18% |
| MMM | 3M | $90.8B | 25.67 | 3.60 | 14.0% | -1.54% |
| BSX | Boston Scientific | $63.2B | 18.07 | 3.00 | 16.6% | -1.71% |
| BDX | Becton Dickinson | $54.0B | 57.37 | 2.59 | 4.5% | -0.20% |
| RMD | ResMed | $31.9B | 20.05 | 5.57 | 27.8% | -2.48% |
| DXCM | DexCom | $30.9B | 31.23 | 6.06 | 19.4% | -2.11% |
| MDLN | Medline Inc. | $29.9B | — | 1.05 | — | +1.40% |
| WST | West Pharmaceutical Services | $28.4B | 44.39 | 8.35 | 18.8% | -0.17% |
| SOLV | Solventum | $14.4B | 10.06 | 1.74 | 17.3% | +0.02% |
| GKOS | Glaukos Corp | $13.8B | — | 19.98 | -24.6% | -2.42% |
| BAX | Baxter International | $13.2B | — | 1.14 | -6.2% | +5.27% |
| PEN | Penumbra Inc | $12.6B | 80.34 | 8.99 | 11.2% | -0.41% |
| PODD | Insulet Corporation | $10.7B | 28.62 | 3.52 | 12.3% | +0.78% |
| GMED | Globus Medical Inc | $10.7B | 19.95 | 3.40 | 17.0% | +0.14% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.